KHINDIVI™ (hydrocortisone) Oral Solution In May 2025, the FDA approved KHINDIVI™ (hydrocortisone) Oral Solution for the treatment of adrenal insufficiency (AI) in pediatric patients ages 5…
Omnipod® 5 App now compatible with Dexcom G7 As of June 2025, the Omnipod® 5 App for iPhone is compatible with the Dexcom G7 Continuous Glucose Monitoring (CGM)…
New Drugs and Therapeutics Update: INVOKANA® (canagliflozin) Prepared by Preneet Cheema Brar, MD, MS and Daniel Mak, MD. INVOKANA® (canagliflozin) In December 2024, the FDA…
New Drugs and Therapeutics Update: VYKAT™ XR (diazoxide choline) Prepared on behalf of PES Drugs and Therapeutics Committee by Dania Al-Hamad, MD, and Neha Patel, DO. …
New Drugs and Therapeutics Update CRENESSITY (crinecerfont) capsules and oral solution On December 13, 2024, the FDA approved CRENESSITYTM (crinecerfont) as adjunctive treatment to glucocorticoid replacement…
New Device Announcement. The twiist™ Automated Insulin Delivery (AID) system has received clearance from FDA 510(k), although the launch date is unclear. This insulin pump has…
Generic Victoza® Teva pharmaceuticals launched a generic version of Victoza® (liraglutide injection 1.8mg ) The generic will cost $469.60 for a pack of two pens and…
In March 2023, the FDA extended the approval of Evinacumab (EVKEEZA©) to children 5-11 years with familial homozygous hypercholesteremia. Evinacumab had been previously approved for 12…
US FDA-approval of VAMOROLONE for Duchenne Muscular Dystrophy (DMD)*-a novel alternative steroid with unique properties. New Drugs and Therapeutics On October 26, 2023, the US…
LUPRON DEPOT-PED 45 mg for 6 months Prepared and edited on behalf of the PES Drug & Therapeutics committee: Shilpa Mehta, MD, Amit Lahoti, MD, Aditi…